Collegium Pharma (COLL) Misses Q3 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 12, 2015 6:02 AM ESTCANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update.
"During the last few months, Collegium achieved a number of important milestones in moving Xtampza ER closer to market launch upon final approval," stated Michael Heffernan, Collegium's CEO. "We were very encouraged by the FDA Advisory Committees' unanimous vote in support of approval of Xtampza ER and subsequently the FDA's tentative approval of the Xtampza ER NDA. Additionally, the commercial team has made significant progress in preparing for... More
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 12, 2015 6:01 AM ESTCANTON, Mass., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2015 and provided a corporate update.
"During the last few months, Collegium achieved a number of important milestones in moving Xtampza ER closer to market launch upon final approval," stated Michael Heffernan, Collegium's CEO. "We were very encouraged by the FDA Advisory Committees' unanimous vote in support of approval of Xtampza ER and subsequently the FDA's tentative approval of the Xtampza ER NDA. Additionally, the commercial team has made significant progress in preparing for... More
